Positron emission tomography of soft tissue sarcomas

Current Opinion in Oncology

Volumn 15, Issue 4, 2003, Pages 327-330

  Israel Mardirosian, Noobar ^a   Adler, Lee P ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE; TRACER;

BENIGN TUMOR; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; CELL ACTIVITY; CELL METABOLISM; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; HUMAN; HUMAN TISSUE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SOFT TISSUE SARCOMA; TUMOR BIOPSY;

FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIOPHARMACEUTICALS; SARCOMA; SOFT TISSUE NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0043240346     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200307000-00008     Document Type: Review

References (32)

1. O'Sullivan B, Bell RS, Bramwell VHC: Sarcoma of the soft tissues. In Oxford Textbook of Oncology. Edited by RL Souhami, et al. New York: Oxford University Press; 2002:2495-2523.
2. Stevens MCG: Malignant mesenchymal tumors of childhood. In Oxford Textbook of Oncology. Edited by RL Souhami, et al. New York: Oxford University Press; 2002:2525-2538.
3. de Saint Aubain Somerhausen N, Fletcher CD: Soft-tissue sarcomas: an update. Eur J Surg Oncol 1999, 25:215-220.
4. Moley JF, Eberlein TJ: Soft-tissue sarcomas. Surg Clin North Am 2000, 80:687-708.
5. Panicek DM, Gatsonis C, Rosenthai DI, et al.: CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: report of the Radiology Diagnostic Oncology Group. Radiology 1997, 202:237-246.
6. Lammertsma AA: PET/SPECT: functional imaging beyond flow. Vision Res 2001, 41:1277-1281.
7. McQuaid K: What is PET? (an overview of principles). Gastroentest Endosc 2002, 55(suppl 7):S51-S52.
8. Watanabe H, Inoue T, Shinozaki T, et al.: PET imaging of musculoskeletal tumours with fluorine-18 alpha-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET. Eur J Nucl Med 2000, 27:1509-1517.
9. Zhang H, Tian M, Oriuchi N, et al.: 11C-choline PET for the detection of bone and soft tissue tumours in comparison with FDG PET. Nucl Med Commun 2003, 24:273-279.
10. Gambhir SS: Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002, 2:683-693.
11. Delbeke D, Martin WH: Positron emission tomography imaging in oncology. Radiol Clin North Am 2001, 39:883-917.
12. Czernin J: Clinical applications of FDG-PET in oncology. Acta Med Austriaca 2002, 29:162-170.
13. Blokland JA, Trindev P, Stokkel MP, et al.: Positron emission tomography: a technical introduction for clinicians. Eur J Radiol 2002, 44:70-75.
14. Eary JF, O'Sullivan F, Powitan Y, et al.: Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging 2002, 29:1149-1154.
15. Schwarzbach MH, Dimitrakopoulou-Strauss A, Willeke F, et al.: Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg 2000, 231:380-386.
16. Schulte M, Brecht-Krauss D, Heymer B, et al.: Grading of tumors and tumor-like lesions of bone: evaluation by FDG PET. J Nucl Med 2000, 41:1695-1701.
17. Aoki J, Watanabe H, Shinozaki T, et al.: FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses. Skeletal Radiol 2003, 32:133-138.
18. Franzius C, Bielack S, Flege S, et al.: Prognostic significance of (18)F-FDG and (99m)Tc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med 2002, 43:1012-1017.
19. Folpe AL, Lyles RH, Sprouse JT, et al.: (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 2000, 6:1279-1287.
20. Dimitrakopoulou-Strauss A, Strauss LG, Schwarzbach M, et al.: Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. J Nucl Med 2001, 42:713-720.
21. Adler LP, Blair HF, Makley JT, et al.: Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991, 32:1508-1512.
22. Aoki J, Watanabe H, Shinozaki T, et al.: FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology 2001, 219:774-777.
23. Bredella MA, Caputo GR, Steinbach LS: Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas. AJR Am J Roentgenol 2002, 179:1145-1150.
24. Hawkins DS, Rajendran JG, Conrad EU III, et al.: Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18] -fluorodeoxy-D-glucose positron emission tomography. Cancer 2002, 94:3277-3284.
25. Schulte M, Brecht-Krauss D, Heymer B, et al.: Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible? Eur J Nucl Med 1999, 26:599-605.
26. Aoki J, Watanabe H, Shinozaki T, et al.: FDG-PET in differential diagnosis and grading of chondrosarcomas. J Comput Assist Tomogr 1999, 23:603-608.
27. Lodge MA, Lucas JD, Marsden PK, et al.: A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999, 26:22-30.
28. Adler LP, Blair HF, Makley JT, et al.: Comparison of PET with CT, MRI, and conventional scintigraphy in a benign and in a malignant soft tissue tumor. Orthopedics 1991, 14:891-894; discussion 894-895.
29. Adler LP, Blair HF, Williams RP, et al.: Grading liposarcomas with PET using [18F]FDG. J Comput Assist Tomogr 1990, 14:960-962.
30. Umesaki N, Tanaka T, Miyama M, et al.: Positron emission tomography with (18)F-fluorodeoxyglucose of uterine sarcoma: a comparison with magnetic resonance imaging and power Doppler imaging. Gynecol Oncol 2001, 80:372-377.
31. Franzius C, Daldrup-Link HE, Wagner-Bohn A, et al.: FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. Ann Oncol 2002, 13:157-160.
32. Franzius C, Sciuk J, Brinkschmidt C, et al.: Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med 2000, 25:874-881.